Velan Capital Investment Management LP historic quarter change: USA Stocks, Added
In share positions in stocks (listed in the US), over 10 quarters from 2023-12-31 to 2026-06-30, Velan Capital Investment Management LP opened 106 positions, added to 66, reduced 35 and sold out of 71.
- Q2 2026: Stock IMMX; Country of operation United States; Class COM; Shares before 740,000.
- Q2 2026: Stock EVMN; Country of operation United States; Class COM SHS; Shares before 446,255.
- Q2 2026: Stock TARA; Country of operation United States; Class COM STK; Shares before 2,834,652.
- Q2 2026: Stock AVTX; Country of operation United States; Class COM NEW; Shares before 185,122.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1848809), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-13); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2021-12-31.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q2 2026 | IMMX
IMMIX BIOPHARMA INC | United States | COM | 740,000 | 1,085,000 | +345,000 | $6,741,400 | $11,186,350 | +$4,444,950 | 2026-08-14 |
|---|
| Q2 2026 | EVMN
EVOMMUNE INC | United States | COM SHS | 446,255 | 451,255 | +5,000 | $10,259,402 | $5,997,179 | -$4,262,223 | 2026-08-14 |
|---|
| Q2 2026 | TARA
PROTARA THERAPEUTICS INC | United States | COM STK | 2,834,652 | 2,844,652 | +10,000 | $14,768,537 | $10,866,571 | -$3,901,966 | 2026-08-14 |
|---|
| Q2 2026 | AVTX
AVALO THERAPEUTICS INC | United States | COM NEW | 185,122 | 324,452 | +139,330 | $2,763,871 | $5,995,873 | +$3,232,002 | 2026-08-14 |
|---|
| Q2 2026 | XNCR
XENCOR INC | United States | COM | 250,000 | 255,000 | +5,000 | $3,015,000 | $4,105,500 | +$1,090,500 | 2026-08-14 |
|---|
| Q2 2026 | LYEL
LYELL IMMUNOPHARMA INC | United States | COM NEW | 102,000 | 105,000 | +3,000 | $2,046,120 | $1,475,250 | -$570,870 | 2026-08-14 |
|---|
| Q2 2026 | NMRA
NEUMORA THERAPEUTICS INC. | United States | COM | 80,000 | 230,000 | +150,000 | $156,000 | $391,000 | +$235,000 | 2026-08-14 |
|---|
| Q2 2026 | MGNX
MACROGENICS INC | United States | COM | 30,000 | 60,000 | +30,000 | $86,700 | $277,200 | +$190,500 | 2026-08-14 |
|---|
| Q2 2026 | KPTI
KARYOPHARM THERAPEUTICS INC | United States | COM NEW | 15,000 | 20,000 | +5,000 | $83,550 | $195,400 | +$111,850 | 2026-08-14 |
|---|
| Q2 2026 | KLRS
KALARIS THERAPEUTICS INC | United States | COM | 18,000 | 25,000 | +7,000 | $103,860 | $101,750 | -$2,110 | 2026-08-14 |
|---|
| Q1 2026 | STRO
SUTRO BIOPHARMA INC | United States | COM SHS | 312,000 | 512,160 | +200,160 | $3,609,840 | $12,757,906 | +$9,148,066 | 2026-05-15 |
|---|
| Q1 2026 | TENX
TENAX THERAPEUTICS INC | United States | COM NEW | 83,333 | 583,333 | +500,000 | $1,015,829 | $9,327,495 | +$8,311,666 | 2026-05-15 |
|---|
| Q1 2026 | IMMX
IMMIX BIOPHARMA INC | United States | COM | 35,000 | 740,000 | +705,000 | $183,050 | $6,741,400 | +$6,558,350 | 2026-05-15 |
|---|
| Q1 2026 | EDSA
EDESA BIOTECH INC | Canada | COM NEW | 687,500 | 827,500 | +140,000 | $976,250 | $4,327,825 | +$3,351,575 | 2026-05-15 |
|---|
| Q1 2026 | CTMX
CYTOMX THERAPEUTICS INC. | United States | COM | 80,000 | 540,000 | +460,000 | $340,800 | $2,538,000 | +$2,197,200 | 2026-05-15 |
|---|
| Q1 2026 | VRDN
VIRIDIAN THERAPEUTICS INC | United States | COM | 86,500 | 91,123 | +4,623 | $2,691,880 | $1,782,366 | -$909,514 | 2026-05-15 |
|---|
| Q1 2026 | ESPR
ESPERION THERAPEUTICS INC NE | United States | COM | 1,210,000 | 1,720,000 | +510,000 | $4,477,000 | $4,712,800 | +$235,800 | 2026-05-15 |
|---|
| Q1 2026 | CRBP
CORBUS PHARMACEUTICALS HLDGS | United States | COM NEW | 13,000 | 26,000 | +13,000 | $105,820 | $244,140 | +$138,320 | 2026-05-15 |
|---|
| Q1 2026 | DTIL
PRECISION BIOSCIENCES INC | United States | COM NEW | 20,000 | 40,000 | +20,000 | $83,200 | $220,000 | +$136,800 | 2026-05-15 |
|---|
| Q1 2026 | PMVP
PMV PHARMACEUTICALS INC | United States | COM | 35,000 | 73,000 | +38,000 | $43,750 | $90,520 | +$46,770 | 2026-05-15 |
|---|
| Q1 2026 | REPL
REPLIMUNE GROUP INC | United States | COM | 15,000 | 20,000 | +5,000 | $145,800 | $153,000 | +$7,200 | 2026-05-15 |
|---|
| Q4 2025 | TARA
PROTARA THERAPEUTICS INC | United States | COM STK | 2,139,000 | 2,834,652 | +695,652 | $9,304,650 | $15,108,695 | +$5,804,045 | 2026-02-13 |
|---|
| Q4 2025 | TERN
TERNS PHARMACEUTICALS INC | United States | COM | 20,000 | 70,000 | +50,000 | $150,200 | $2,828,000 | +$2,677,800 | 2026-02-13 |
|---|
| Q4 2025 | RAPT
RAPT THERAPEUTICS INC | United States | COM NEW | 79,977 | 108,000 | +28,023 | $2,062,607 | $3,657,960 | +$1,595,353 | 2026-02-13 |
|---|
| Q4 2025 | LNTH
LANTHEUS HLDGS INC | United States | COM | 73,545 | 74,687 | +1,142 | $3,772,123 | $4,970,420 | +$1,198,297 | 2026-02-13 |
|---|
| Q3 2025 | MLYS
MINERALYS THERAPEUTICS INC | United States | COM | 174,600 | 175,600 | +1,000 | $2,362,338 | $6,658,752 | +$4,296,414 | 2025-11-14 |
|---|
| Q3 2025 | HRTX
HERON THERAPEUTICS INC | United States | COM | 6,986,744 | 8,753,290 | +1,766,546 | $14,462,560 | $11,029,145 | -$3,433,415 | 2025-11-14 |
|---|
| Q3 2025 | NSPR
INSPIREMD INC | | COM | 904,029 | 2,143,698 | +1,239,669 | $2,052,146 | $5,166,312 | +$3,114,166 | 2025-11-14 |
|---|
| Q3 2025 | CTMX
CYTOMX THERAPEUTICS INC | United States | COM | 75,000 | 80,000 | +5,000 | $170,250 | $255,200 | +$84,950 | 2025-11-14 |
|---|
| Q3 2025 | NRIX
NURIX THERAPEUTICS INC | United States | COM | 10,000 | 16,000 | +6,000 | $113,900 | $147,840 | +$33,940 | 2025-11-14 |
|---|
| Q3 2025 | IMMX
IMMIX BIOPHARMA INC | United States | COM | 25,000 | 35,000 | +10,000 | $51,750 | $73,150 | +$21,400 | 2025-11-14 |
|---|
| Q3 2025 | ELDN
ELEDON PHARMACEUTICALS INC | United States | COM | 338,973 | 346,973 | +8,000 | $918,617 | $898,660 | -$19,957 | 2025-11-14 |
|---|
| Q3 2025 | GERN
GERON CORP | United States | COM | 70,000 | 80,000 | +10,000 | $98,700 | $109,600 | +$10,900 | 2025-11-14 |
|---|
| Q2 2025 | ELDN
ELEDONPHARMACEUTICALSINC | United States | COM | 323,973 | 338,973 | +15,000 | $1,098,268 | $918,617 | -$179,651 | 2025-08-14 |
|---|
| Q2 2025 | REPL
REPLIMUNEGROUPINC | United States | COM | 182,083 | 183,083 | +1,000 | $1,775,309 | $1,700,841 | -$74,468 | 2025-08-14 |
|---|
| Q2 2025 | LRMR
LARIMARTHERAPEUTICSINC | United States | COM | 28,000 | 33,000 | +5,000 | $60,200 | $95,370 | +$35,170 | 2025-08-14 |
|---|
| Q2 2025 | MLYS
MINERALYSTHERAPEUTICSINC | United States | COM | 150,600 | 174,600 | +24,000 | $2,391,528 | $2,362,338 | -$29,190 | 2025-08-14 |
|---|
| Q2 2025 | TERN
TERNSPHARMACEUTICALSINC | United States | COM | 17,000 | 20,000 | +3,000 | $46,920 | $74,600 | +$27,680 | 2025-08-14 |
|---|
| Q2 2025 | OVID
OVIDTHERAPEUTICSINC | United States | COM | 97,000 | 160,000 | +63,000 | $30,254 | $52,784 | +$22,530 | 2025-08-14 |
|---|
| Q2 2025 | ERAS
ERASCAINC | United States | COM | 50,000 | 65,000 | +15,000 | $68,500 | $82,550 | +$14,050 | 2025-08-14 |
|---|
| Q2 2025 | DSGN
DESIGNTHERAPEUTICSINC | United States | COM | 14,000 | 20,000 | +6,000 | $54,040 | $67,400 | +$13,360 | 2025-08-14 |
|---|
| Q2 2025 | CNTX
CONTEXTTHERAPEUTICSINC | United States | COM | 90,000 | 100,000 | +10,000 | $55,080 | $65,520 | +$10,440 | 2025-08-14 |
|---|
| Q1 2025 | ZVRA
ZEVRA THERAPEUTICS INC | United States | COM NEW | 300,000 | 665,000 | +365,000 | $2,502,000 | $4,980,850 | +$2,478,850 | 2025-05-15 |
|---|
| Q1 2025 | TRML
TOURMALINE BIO INC | United States | COM | 423,795 | 455,412 | +31,617 | $8,594,562 | $6,926,817 | -$1,667,745 | 2025-05-15 |
|---|
| Q1 2025 | TARA
PROTARA THERAPEUTICS INC | United States | COM STK | 1,579,000 | 1,667,800 | +88,800 | $8,337,120 | $7,104,828 | -$1,232,292 | 2025-05-15 |
|---|
| Q1 2025 | GERN
GERON CORP | United States | COM | 49,000 | 655,000 | +606,000 | $173,460 | $1,041,450 | +$867,990 | 2025-05-15 |
|---|
| Q1 2025 | REPL
REPLIMUNE GROUP INC | United States | COM | 181,367 | 182,083 | +716 | $2,196,354 | $1,775,309 | -$421,045 | 2025-05-15 |
|---|
| Q1 2025 | CRBP
CORBUS PHARMACEUTICALS HLDGS | United States | COM NEW | 56,700 | 59,000 | +2,300 | $669,060 | $313,290 | -$355,770 | 2025-05-15 |
|---|
| Q1 2025 | AVTX
AVALO THERAPEUTICS INC | United States | COM NEW | 109,972 | 111,972 | +2,000 | $817,092 | $896,896 | +$79,804 | 2025-05-15 |
|---|
| Q1 2025 | PRQR
PROQR THRAPEUTICS N V | | SHS EURO | 40,500 | 45,000 | +4,500 | $107,325 | $59,850 | -$47,475 | 2025-05-15 |
|---|
| Q1 2025 | OVID
OVID THERAPEUTICS INC | United States | COM | 70,000 | 97,000 | +27,000 | $65,359 | $30,254 | -$35,105 | 2025-05-15 |
|---|
| Q1 2025 | VTYX
VENTYX BIOSCIENCES INC | United States | COM | 35,000 | 40,000 | +5,000 | $76,650 | $46,000 | -$30,650 | 2025-05-15 |
|---|
| Q1 2025 | FDMT
4D MOLECULAR THERAPEUTICS IN | United States | COM | 10,000 | 12,000 | +2,000 | $55,700 | $38,760 | -$16,940 | 2025-05-15 |
|---|
| Q1 2025 | ACRS
ACLARIS THERAPEUTICS INC | United States | COM | 27,000 | 35,000 | +8,000 | $66,960 | $53,550 | -$13,410 | 2025-05-15 |
|---|
| Q1 2025 | CTMX
CYTOMX THERAPEUTICS INC | United States | COM | 35,000 | 75,000 | +40,000 | $36,050 | $47,685 | +$11,635 | 2025-05-15 |
|---|
| Q1 2025 | LRMR
LARIMAR THERAPEUTICS INC | United States | COM | 18,000 | 28,000 | +10,000 | $69,660 | $60,200 | -$9,460 | 2025-05-15 |
|---|
| Q4 2024 | TARA
PROTARA THERAPEUTICS INC | United States | COM STK | 574,000 | 1,579,000 | +1,005,000 | $1,050,420 | $8,337,120 | +$7,286,700 | 2025-02-14 |
|---|
| Q4 2024 | ZVRA
ZEVRA THERAPEUTICS INC | United States | COM NEW | 200,000 | 300,000 | +100,000 | $1,388,000 | $2,502,000 | +$1,114,000 | 2025-02-14 |
|---|
| Q4 2024 | CRBP
CORBUS PHARMACEUTICALS HLDGS | United States | COM NEW | 50,000 | 56,700 | +6,700 | $1,031,500 | $669,060 | -$362,440 | 2025-02-14 |
|---|
| Q4 2024 | TRML
TOURMALINE BIO INC | United States | COM | 331,190 | 423,795 | +92,605 | $8,514,895 | $8,594,562 | +$79,667 | 2025-02-14 |
|---|
| Q3 2024 | TRML
TOURMALINE BIO INC | United States | COM | 319,080 | 331,190 | +12,110 | $4,103,369 | $8,514,895 | +$4,411,526 | 2024-11-14 |
|---|
| Q3 2024 | TELA
TELA BIO INC | United States | COM | 746,087 | 747,410 | +1,323 | $3,506,609 | $1,890,947 | -$1,615,662 | 2024-11-14 |
|---|
| Q3 2024 | TARA
PROTARA THERAPEUTICS INC | United States | COM STK | 480,000 | 574,000 | +94,000 | $998,400 | $1,050,420 | +$52,020 | 2024-11-14 |
|---|
| Q2 2024 | RZLT
REZOLUTE INC | United States | COM NEW | 400,000 | 800,000 | +400,000 | $1,020,000 | $3,440,000 | +$2,420,000 | 2024-08-14 |
|---|
| Q1 2024 | PRAX
PRAXIS PRECISION MEDICINES I | United States | COM NEW | 345,666 | 350,666 | +5,000 | $7,701,438 | $21,397,639 | +$13,696,201 | 2024-05-14 |
|---|
| Q1 2024 | TELA
TELA BIO INC | United States | COM | 77,500 | 746,087 | +668,587 | $513,050 | $4,230,313 | +$3,717,263 | 2024-05-14 |
|---|